ST Recognizes 100 Year Anniversary

GREENWICH, Conn., PRNewswire/ — Spencer Trask & Co., a privately held advanced technology company, is recognizing the 100 year anniversary of Albert Einstein’s publication of his paper on quantum theory of radiation with a contribution to the Institute for Advanced Study, where Einstein served as a professor from 1935-1955. Spencer Trask Chairman Kevin Kimberlin helped achieve Einstein’s vision of harnessing the power of light as the co-founder of Ciena.

On March 3, 1917, Einstein postulated how light can result from stimulating excited atoms. As proven by Gordon Gould 60 years later, this “light amplification by stimulated emission of radiation” would give way to the invention of the Laser and Optical Amplifier, which are the two foundational elements of the optical communications networks which transport much of the global Internet traffic.

Gould would go on to start the fiber optic communications company Optelecom. His protege and head of Optelecom’s Light Optics Division, Dr. David Huber, began working on a new technology called Dense Wavelength Division Multiplexing.

“I first met Huber in the early ’90s at Optelecom, where he demonstrated his light-based communication system,” said Kevin Kimberlin, Chairman of Spencer Trask & Co. “Impressed, I offered to help him develop the system. Together, we founded a new company called Ciena, which was the first to commercialize high capacity optical networking systems based on the optical amplifier,” Kimberlin explained. This was the beginning of the internet as we know and use it today.

About Spencer Trask & Company

Spencer Trask & Co. is a privately held advanced technology development company. The firm works with entrepreneurs, CEOs and corporate partners to start and grow high impact ventures. Spencer Trask & Co. has been instrumental in the formative stage of companies that pioneered many technological and scientific advancements in the field of genomics, the transformation of healthcare, the Internet and open innovation.

Immune Response Corporation

Pioneering the vaccine revolution

Developing new vaccines to fight AIDS and cancer

The first FDA-approved cancer vaccine, an immune therapy made from the patient’s own cells.

Polio vaccine hero Dr. Jonas Salk and our Chairman founded The Immune Response Corporation. They recruited the team, attracted $350 million from investors and corporate partners, and developed groundbreaking immune therapies.

IRC technology was key to the first FDA-approved cancer vaccine, sipuleucel-T. More than 40,000 patients have received this prostate cancer therapy, which appears to be more effective in African American men, with a 48% percent reduction in death, compared to white men. The first cell-based immunotherapy, this approval opened the floodgates for immunotherapeutics, today the largest category of pharmaceuticals.